These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16113088)

  • 1. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience.
    Miller WR; Anderson TJ; White S; Evans D; Krause A; Dixon JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S119-23. PubMed ID: 16113088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
    Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B
    Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
    Johnston SR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
    Thomas JS; Julian HS; Green RV; Cameron DA; Dixon MJ
    Histopathology; 2007 Aug; 51(2):219-26. PubMed ID: 17650216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy.
    Barrett-Lee PJ
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S125-33. PubMed ID: 16113089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
    Bhatnagar AS
    Breast; 2006 Feb; 15 Suppl 1():S3-13. PubMed ID: 16500235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.